Lefisyo

Levomethadone, the active ingredient in Lefisyo, is a synthetic opioid presented as an oral dosage form for oral use. It is used in the management of opioid dependence and chronic pain in adult patients.

GNH USA supplies Lefisyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadone is employed in opioid‑related disorders and severe pain management.

Opioid dependence: helps maintain abstinence and reduce withdrawal symptoms. Chronic pain: provides long‑acting analgesia for severe persistent pain. Detoxification: assists in controlled tapering of opioid use.

Levomethadone may cause a range of adverse reactions.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Drowsiness: increased sedation. - Nausea: gastrointestinal upset. - Sweating: excessive perspiration. - Dry mouth: reduced salivation. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - QT interval prolongation: risk of cardiac arrhythmia. - Seizures: rare neurologic events. - Severe hypotension: marked blood pressure drop. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatotoxicity: liver enzyme elevation.

Levomethadone requires careful monitoring and specific safety measures. - Contraindication: avoid use in patients with known hypersensitivity to methadone or its enantiomers. - Monitoring: regular assessment of respiratory function and cardiac rhythm, especially QT interval. - Drug interactions: avoid concurrent use with other central nervous system depressants. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levomethadone can interact with several medicines, altering its safety profile.

Major Interactions (Avoid): - Benzodiazepines, barbiturates, or alcohol: additive CNS depression. - MAO inhibitors: risk of severe serotonin syndrome. - QT‑prolonging agents (e.g., quinidine, haloperidol): increased cardiac arrhythmia risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise levomethadone levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antidepressants (e.g., SSRIs, SNRIs): potential for enhanced serotonergic effects.